Obesity News

Of adults with type 2 diabetes who used an incretin-based medication, the majority received an injectable GLP-1 receptor agonist in the first quarter of 2022, according to study findings.

Last year, the CDC updated its 22-year-old pediatric BMI-for-age growth charts to add BMIs above the 97th percentile for the first time in order to track severe obesity in children aged 2 to 19 years.

Researchers estimated that semaglutide could cut the obesity prevalence in the United States by about 46% and prevent more than 1.5 million CVD events over 10 years when given to eligible patients with overweight or obesity.

Recent reports in the media and legal action have raised questions about the safety of popular weight-loss drugs, particularly about whether they increase the risk for events such as gastroparesis and gastroenteritis.

In adults with HF with preserved ejection fraction and obesity, semaglutide 2.4 mg significantly improved HF-related symptoms and physical limitations and was associated with greater weight loss compared with placebo, researchers reported.

Beyond obesity's association with cardiovascular diseases and metabolic disorders, mounting evidence reveals a deep-rooted connection between obesity and cancer risk.

DANA POINT, Calif. — In this Healio video exclusive, Fatima Cody Stanford, MD, MPA, MPH, MBA, discusses considerations clinicians must make regarding women with obesity.

A new generation of obesity drugs is changing the treatment landscape for patients and providers, with options that can lead to weight loss unheard of just a few years ago.

Last month, WHO’s International Agency for Research on Cancer declared aspartame — a popular artificial sweetener that is used in products like soft drinks, chewing gum and ice cream — a potential carcinogen.

Childhood cancer survivors in France are less likely to develop obesity compared with the country’s general population, according to a study published in Obesity.